Radiopharmaceutical developer Navidea Biopharmaceuticals has been awarded a grant from the National Institute on Aging (NIA) of the U.S. National Institutes of Health (NIH).
The award is a Small Business Innovation Research (SBIR) grant for developing the company's NAV4694 beta-amyloid imaging agent. The grant will partially support a phase IIB clinical study evaluating NAV4694 as a diagnostic imaging agent that may aid physicians in identifying those individuals with mild cognitive impairment who are at greatest risk of progressing to Alzheimer's disease.
If fully funded, the grant has the potential to provide up to $2.3 million in support through the conclusion of the clinical study, according to Navidea.
